Immunic, Inc. (IMUX) Stock Analysis — Probabli.AI
AI-powered analysis for IMUX (Immunic, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $1.29 · Market cap: $160.5M · AI outlook: Bullish
Immunic, Inc. (IMUX) demonstrates promise as an innovative biopharmaceutical company with impactful clinical progress, esteemed analyst enthusiasm, and a valuable drug pipeline. While competitive and cost-related risks exist, the potential market and revenue from their primary candidate IMU-838 present substantial medium-to-long-term value. Given its strong fundamentals and anticipated regulatory…
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 25% · Bear 20%
- 1-year price estimates — P10: $1 / P50: $3 / P90: $5
- Immunic, Inc. has several bullish indicators within the one-year timeframe, such as the strong analyst consensus rating of STRONG BUY, clinical trial successes, and the recent upward price movement. However, risks exist…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $2 / P50: $8 / P90: $15
SWOT Highlights
- Strength: Promising clinical trial results and robust pipeline
- Strength: Strong analyst support with favorable price targets
- Risk: Negative average EPS surprises historically
- Risk: Concerns over rising R&D costs in the medium term
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
5 Wall Street analysts rate IMUX a STRONG BUY with a mean price target of $4.25.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
IMUX forecast details · IMUX sentiment details · IMUX insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.